All In Biotech

NDA 020892 · Endo Operations

Valstar Preservative Free

Valrubicin · Intravesical

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 7, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Sep 25, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

7

4 Phase 3, 0 recruiting

FAERS reports

178

30 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2024.

VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ( 1 )

Mechanism: Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G 2 . Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 2, 2013 Supplement 16 · Efficacy Letter
  • Sep 25, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
1 products under this application
  • VALSTAR PRESERVATIVE FREE · VALRUBICIN 40MG/ML · SOLUTION, INTRAVESICAL · Prescription · TE AO

Clinical trials

Interventional ClinicalTrials.gov studies with "Valrubicin" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • underdose26
  • bladder instillation procedure24
  • accidental exposure to product23
  • urge incontinence20
  • bladder spasm13
  • urinary incontinence11
  • pain9
  • dysuria8
  • burning sensation7
  • drug ineffective7
  • arthralgia6
  • fatigue6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20121
201379
201426
201515
20165
201710
201818
20193
20204
20215
20222
20233
20242
20253
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 13, 2026

    Valstar Preservative Free, Solution, 40 mg/1 mL (NDC 67979-001-01). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Endo Operations

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.